Solutions for
Business Intelligence

BizInt Smart Charts

PhMTI
Pharma & MedTech
Information

How Big is Our Pipeline?

Finding answers in Pharma and MedTech Information

Matt Eberle, Lead Developer, Analytics & Custom Solutions

September 2025

www.bizint.com

7:30

CI

Certain Individual

Yesterday 4:27 PM

Hey- How big is our pipeline?

Wait- forgot we list it on our website. NVM

But, maybe that's not the answer they need. Who wants to know?

External? Internal? How about subsidiaries? What phase?

So...Google it?

Who wants to know?

- External
  - Investors
  - Partners
  - Competitors
  - Press
- Internal
  - Marketing
  - CI
  - R&D
  - C Suite

Who wants to show they know?

- inspire cross-functional collaboration
- highlight the importance of sources and tools
- position the information group as thought leaders within the organization.

It makes a difference…

- Where do you look?
  - Is there a single best source of truth?
  - Who decides active/inactive status?
- Who's asking?
  - What counts as "our" drug?
  - What counts as a single drug?

Where do you look?



© 2025 BizInt Solutions, Inc | www.bizint.com

Where do you look?



© 2025 Bizint Solutions, Inc | www.bizint.com

Where do you look?



© 2025

Where do you look?



© 2025

Where do you look?

Query: Company = Amgen.
Any inclusion of subsidiaries was database-dependent

Total # of Records: 2,114
Total # of Drugs: 1,292 - 822 Duplicates??

Database	Records Retrieved
AdisInsight Drugs	490
Citeline Pharmaprojects	652
Cortellis from Clarivate Analytics	530
GlobalData Drugs	442

Every source is right, but not complete

Number of sources	# of Drugs (Common Drug Names)	% of Total Drugs
All sources	179	14%
3 sources	56	4%
2 sources	85	7%
A single source	972	75%

When is a drug still active/still in our pipeline?

	Drug Name	Database	Developer	Highest Phase (Normalized)
168a	AMG 119	AdisInsight Drugs	Amgen	It's Complicated
168b	AMG-119	Citeline Pharmaprojects	Amgen	It's Complicated
168c	AMG-119	Cortellis from Clarivate Analytics	Amgen Inc	It's Complicated
168d	AMG-119	GlobalData Drugs	Kite Pharma Inc	It's Complicated

© 2025 BizInt Solutions, Inc | www.bizint.com

Records: Amgen 25-Aug-2022

149: (PP) AMG-119

AMG-119

AMG 119, AMG-119, AMG119, DLL3 CAR-T cells, Amgen, DLL3 CAR-T therapy, Amgen, DLL3 chimaeric antigen receptor therapy, Amgen

Drug Key: 148470
Latest Change Date: 2021-12-27

Overview

Amgen has suspended the development of AMG-119, a chimaeric antigen receptor-T cell (CAR-T) therapy targeting DLL3, for small-cell lung cancer (SCLC) due to enrollment hold; it may potentially resume and no active subjects are on trial (ClinicalTrials, 8 Jan 2018 & 23 Mar 2021, https://clinicaltrials.gov/show/NCT03392064; 2nd Qtr Res presentation, Amgen, 30 Jul 2019, Slide 29, http://investors.amgen.com/static-files/e1393dc2-f372-4dcc-992a-afc36a03b8fa; Company pipeline, Amgegn, 14 Feb 2020, Page 6, https://www.amgenpipeline.com/-/media/themes/amgen/amgenpipeline-com/amgenpipeline-com/pdf/amgen-pipeline-chart.pdf).

Company Status

Company	Status
Amgen	Suspended
BeiGene	Suspended

Disease Status

Disease	Status
Cancer, lung, small cell	Suspended

Latest Change: Suspension of Phase I trial (20170124) confirmed per NCT03392064

Key Events

Date	Event	Detail
2021-03-23	Development Suspended	Phase I Clinical Trial
2020-02-14	Development Restarted	Phase I Clinical Trial
2020-01-02	New Licensee	BeiGene; China
2019-12-18	Orphan Drug Status Granted	The US; Cancer, lung, small cell
2019-07-30	Development Suspended	Phase I Clinical Trial

Records: Amgen 25-Aug-2022

148: (RDI) AMG 119

As at July 2021, no recent reports of development had been identified for phase-I development in Small-cell-lung-cancer (Second-line therapy or greater) in USA (IV, Infusion).

Key Development Milestones

As of March 2021, Amgen suspended a phase I trial that was designed to evaluate the safety and tolerability of AMG 119 in adults with relapsed/refractory small cell lung cancer (20170124; NCT03392064). The trial was initiated in June 2018, and intended to enrol approximately 41 patients in the US.

Drug Development History (Extended)

Event Date	Update Type	Event	Update Date
2021-11-26	Active Status Review	AMG 119 is still in phase-I trials for Small-cell-lung-cancer(Second-line therapy or greater) in USA (IV,	2021-11-26

Records: Amgen 25-Aug-2022

150: (COR) AMG-119

Other Actions: T-lymphocyte stimulator; Immunostimulant; Anticancer; Genetically engineered autologous cell therapy

Technologies: Infusion; Protein fusion; Immuno-oncology; Biological therapeutic; Chimeric antigen receptor T cell therapy; Intravenous formulation; T-lymphocyte; Receptor chimeric

Development Summary

Amgen , in collaboration with Kite Pharma (a subsidiary of Gilead), is developing AMG-119, an immunotherapy comprising autologous T cells genetically engineered to express a chimeric antigen receptor (CAR) against delta-like ligand 3 (DLL3), based on Kite's engineered autologous cell therapy (eACT) platform, for the potential treatment of small-cell lung cancer (SCLC) [1623940], [2018501], [2027373]. In July 2018, a phase I trial in relapsed/refractory SCLC was initiated [2018501]. In July 2019, Amgen announced that it was 'pausing' the DLL3 CAR T program in the Kite collaboration to focus on bispecific T-cell engager (BiTE) drugs [2182739], [2182740]; however, in December 2019, Orphan designation was granted in the US, so it was presumed at that time, that development had been reinstated [2232852]. In February 2020, the phase I trial was ongoing, but no longer recruiting participants, and had enrolled 6 patients, rather than the planned 41 [2018501]. In March 2021, the trial was listed as suspended, possibly to resume in the future [2018501]. In August 2021, the drug was still listed in phase I on the company pipeline [2504589].

Latest Change

24-Mar-2022 (Development profile section source updates)

© 2025 BizInt Solutions, Inc | www.bizint.com

What counts as a single drug?

	Drug Name	Drug Name(s)	Database	Update Date
1 Link	**Research programme: TRPV1 cation channel antagonists - Amgen**	Research programme: TRPV1 cation channel antagonists - Amgen AMG 0347 AMG 2674 AMG 8163 AMG 9810 AMG8562 TRPV1 cation channel antagonists Amgen	AdisInsight Drugs	2008-12-08
2 Link	**AMG 517**	AMG 517 AMG517	AdisInsight Drugs	2007-11-23
3 Link	**AMG-628**	AMG-628	Citeline Pharmaprojects	2008-08-21
4 Link	**AMG-517**	AMG-517 AMG 517 TRPV1 antagonists, Amgen VR1 antagonist, Amgen	Citeline Pharmaprojects	2008-08-21
5 Link	**vanilloid receptor-1 antagonists (pain), Amgen**	vanilloid receptor-1 antagonists (pain), Amgen AMG-9810 TRPV1 antagonists, Amgen VR1 antagonists (pain), Amgen AMG-0347 AMG-517 AMG-2674 AMG-8163 AMG-3731 AMG-1623 JYL-1421 AMG-628 AMG-8562	Cortellis from Clarivate Analytics	2012-11-16
6 Link	**AMG-517**	AMG-517 AMG 517 AMG517	GlobalData Drugs	2017-08-31
7 Link	**AMG-3731**	AMG-3731 AMG 3731 AMG3731	GlobalData Drugs	2017-09-14
8 Link	**AMG-8163**	AMG-8163 AMG 8163 AMG8163	GlobalData Drugs	2017-09-15
9 Link	**AMG-0347**	AMG-0347 AMG 0347 AMG0347	GlobalData Drugs	2017-09-13

© 2025 BizInt Solutions, Inc | www.bizint.com

What counts as a single drug? A single record?

	Drug Name	Drug Name(s)	Database
1	**Research programme: TRPV1 cation channel antagonists - Amgen**	Research programme: TRPV1 cation channel antagonists - Amgen AMG 0347 AMG 2674 AMG 8163 AMG 9810 AMG8562 TRPV1 cation channel antagonists Amgen	AdisInsigh
2	**AMG 517**	AMG 517	AdisInsigh
5	**vanilloid receptor-1 antagonists (pain), Amgen**	vanilloid receptor-1 antagonists (pain), Amgen AMG-9810 TRPV1 antagonists, Amgen VR1 antagonists (pain), Amgen AMG-0347 AMG-517 AMG-2674 AMG-8163 AMG-3731 AMG-1623 JYL-1421 AMG-628 AMG-8562	Cortellis from Clarivate Analyti

© 2025

What counts as a single drug? A lab code?

	Drug Name	Drug Name(s)	Database	Update Date
1 Link	**Research programme: TRPV1 cation channel antagonists - Amgen**	Research programme: TRPV1 cation channel antagonists - Amgen AMG 0347 AMG 2674 AMG 8163	AdisInsight Drugs	2008-12-08
6 Link	**AMG-517**	AMG-517 AMG 517 AMG517	GlobalData Drugs	2017-08-31
7 Link	**AMG-3731**	AMG-3731 AMG 3731 AMG3731	GlobalData Drugs	2017-09-14
8 Link	**AMG-8163**	AMG-8163 AMG 8163 AMG8163	GlobalData Drugs	2017-09-15
9 Link	**AMG-0347**	AMG-0347 AMG 0347 AMG0347	GlobalData Drugs	2017-09-13

What counts as a company's drug?

	Common Drug Name	Database	Companies (Roles)	Company (Key)	Highest Phase (Normalized)
110a	NT 501	AdisInsight Drugs	Neurotech USA (Originator) Neurotech USA (Owner)		Phase 3

140a: (RDI) NT 501

the patient if required.

Company Agreements

In January 2002, Neurotech SA obtained exclusive rights from Amgen Inc. to use CNTF in all ophthalmological indications. Neurotech has also been granted an exclusive license from the Regents of the University of California under a patent claiming the use of CNTF in degenerative eye disorders.

110d	NT 501	GlobalData Drugs	Amgen Inc (Primary) Neurotech Pharmaceuticals Inc (Licensee) University of California (Licensor)	Amgen Inc	Phase 3

What counts as our drug? Our lab code prefix?

Common Drug Name	Developer	Companies (Roles)	Company (Key)	Database
AMG 119	Amgen	Amgen (Originator) Amgen (Owner)		AdisInsight Drugs
AMG 119	Amgen	Amgen (Originator) BeiGene (Licensee)		Citeline Pharmaprojects
AMG 119	Amgen Inc	Amgen Inc (Originator) Kite Pharma Inc		Cortellis from Clarivate Analytics
AMG 119	Kite Pharma Inc	Gilead Sciences Inc (Primary) Kite Pharma Inc (Developer) Amgen Inc (Partner)	Gilead Sciences Inc	GlobalData Drugs

© 2025 BizInt Solutions, Inc | www.bizint.com

What counts as our drug? Our lab code prefix?

Common Drug Name	Developer	Companies (Roles)	Company (Key)	Database
AMG 119				
AMG 119				
AMG 119				
AMG 119				

173c: (COR) AMG-119

autologous cell therapy

Technologies: Infusion; Protein fusion; Immuno-oncology; Biological therapeutic; Chimeric antigen receptor T cell therapy; Intravenous formulation; T-lymphocyte; Receptor chimeric

Development Summary

Amgen , in collaboration with Kite Pharma (a subsidiary of Gilead), is developing AMG-119, an immunotherapy comprising autologous T cells genetically engineered to express a chimeric antigen receptor (CAR) against delta-like ligand 3 (DLL3), based on Kite's engineered autologous cell therapy (eACT) platform, for the potential treatment of small-cell lung cancer (SCLC) [1623940], [2018501], [2027373]. In July 2018, a phase I trial in relapsed/refractory SCLC was initiated [2018501]. In July 2019, Amgen announced that it was 'pausing' the DLL3 CAR T program in the Kite collaboration to

© 2025 BizInt Solutions, Inc | www.bizint.com

Lab code matches, but is this in their pipeline?

Common Drug Name	Developer	Companies (Roles)	Company (Key)	Database	Highest Phase (Normalized)	Update Date
AMG 634	Celgene Corporation	Celgene Corporation (Originator) Medicines Development for Global Health (Licensee) Amgen (Owner) National Institute of Allergy and Infectious Diseases (Collaborator)		AdisInsight Drugs	Phase 2	2020-12-28
AMG 634	Amgen	Amgen (Originator) Celgene (Licensee)		Citeline Pharmaprojects	No Development Reported	2022-05-16
AMG 634	Celgene Corporation	Celgene Corporation (Originator) Medicines Development Ltd		Cortellis from Clarivate Analytics	Phase 2	2022-03-11
AMG 634	Amgen Inc	Medicines Development for Global H (Primary) Celgene Corp Amgen Inc (Licensor)	Medicines Development for Global Health Ltd	GlobalData Drugs	Phase 2	2022-08-18

Lab code matches, but is this in their pipeline?

Common Drug Name	Developer	Companies (Roles)	Company (Key)	Database	Highest Phase (Normalized)	Update Date
AMG 634	Celgene Corporati					

180a: (RD

Commercial Introdu

AMG 634 (formerly
inhibitory drug by A
inflammatory mole
degrade cyclic ade
of tumour necrosis

In November 2019,

As of June, Amgen
organisations for cl

GlobalData. Companies Diseases Countries Databases Analysis News Tools Services Webinars New Strategic Intel

Deal in Brief

Medicines Development for Global Health (MDGH), a non-profit biopharmaceutical company, has entered into a license agreement with Amgen Inc, a biopharmaceutical company, for AMG 634, a phosphodiesterase type 4 (PDE4) inhibitor being investigated for the treatment of tuberculosis (TB) and erythema nodosum leprosum (ENL), an inflammatory cutaneous and systemic complication of leprosy.

The compound is in Phase 2 development with studies led by the Aurum Institute NPC (TB study) and The Leprosy Mission Nepal (ENL study). Amgen had acquired AMG 634 (formerly CC-11050) as part of its acquisition of Otezla® (apremilast) from Celgene in 2019.

Under the terms of the agreement, MDGH will assume full responsibility for the further development and commercialization of AMG 634.

© 2025 BizInt Solutions, Inc

Meeting the challenges

- Gather data from multiple drug pipeline databases
- Identify which records cover the same drug
- Create a single combined report
- Integrate all sources so that each pipeline drug appears once and resolve discrepancies

Amgen clinical stage pipeline



Amgen Clinical Stage Pipeline

Phase 1		Phase 2	Phase 3
AMG 133	KITE796	acapatamab	bemarituzumab
AMG 199	AMG 224	AMB 051	brazikumab
AMG 340	AMG 256	AMG 729	eculizumab
AMG 509	AMG 609	BMS 986258	epratuzumab
AMG 910	FPT 155	Cabiralizumab	ganitumab
AMG 994	TNB-486	efavaleukin alfa	ustekinumab
AMG330	AMG 650	namilumab	aflibercept
AMG404	AMG 786	ordesikimab	
AMG427	BGE105	tarlatamab	
AZD 8630	CK-136	CDX 301	
CX 904		olpasiran	
FPA150		Rozibafusp alfa	
OBT-076		AMG 193	
pacanalotamab		AMG 319	
pasotuxizumab		AMG 634	
TNB 383B			
TNB-738			
XmAb-968			
AMG 119			
G-207			

Type of Compound

- Antibody
- Cell/Gene therapy
- Other Biologic
- Small molecule

VP-SCE

Piano Chart

Amgen Clinical Stage Pipeline

Antibody		Cell/Gene therapy	Other Biologic	Small molecule
AMG 133	AMG 729	AMG 119	AMG 224	AMG 650
AMG 199	BMS 986258	G-207	AMG 256	AMG 786
AMG 340	Cabiralizumab	KITE796	AMG 609	BGE105
AMG 509	efavaleukin alfa		FPT 155	CK-136
AMG 910	namilumab		TNB-486	AMG 193
AMG 994	ordesikimab		CDX 301	AMG 319
AMG330	tarlatamab		olpasiran	AMG 634
AMG404	bemarituzumab		Rozibafusp alfa	
AMG427	brazikumab		aflibercept	
AZD 8630	eculizumab			
CX 904	epratuzumab			
FPA150	ganitumab			
OBT-076	ustekinumab			
pacanalotamab				
pasotuxizumab				
TNB 383B				
TNB-738				
XmAb-968				
acapatamab				
AMB 051				

Highest Phase

- Phase 1
- Phase 2
- Phase 3

VP-SCE Piano Chart

Amgen clinical stage - drug type by status



Amgen Clinical Stage Pipeline – Mechanism of Action



BizDash | Drug Landscapes

Leveraging your subscriptions, we collect data on your landscape topic from the leading pipeline databases.

- GlobalData - Pipeline
- AdisInsight - Drugs
- Cortellis - Competitive Intelligence, Drug Discovery Intelligence
- Citeline - Pharmaprojects
- PatSnap - Synapse

BizDash analysts use industry-leading algorithms to process, integrate, and visualize the data.

- Combine search results and map columns with similar data.
- Identify related drug records across databases.
- Evaluate discrepancies and integrate data.
- Clean up, analyze, and visualize integrated data.
- Export drug landscapes to PowerPoint, Word, Excel, and BizDash Viewer.

You receive high-quality drug landscapes to inform your CI analysis.

- PowerPoint slides with visualizations and search strategy:
  - Bullseyes and Piano Charts (editable in PowerPoint)
  - Bubble Charts and Word Clouds (images in PowerPoint)
- Tabular reports with full integrated data, in Excel, Word, and BizDash Viewer.

Thank you very much!

Questions?

bizint.com/surfing

bizint.com/bizdash

BizDash
Drug Landscapes